Bain Capital Life Sciences Investors LLC Sells 686,579 Shares of Nautilus Biotechnology, Inc. $NAUT

Key Points

• Bain Capital Life Sciences Investors LLC has reduced its stake in Nautilus Biotechnology by 39% in the first quarter, now holding approximately 1,072,421 shares worth $923,000.
• Institutional ownership of Nautilus Biotechnology stands at 50.71%, with several investors increasing their stakes, including Bank of America and Barclays, who boosted their holdings by 37.1% and 17.9%, respectively.
• Nautilus Biotechnology's stock recently traded at $0.67, having a 12-month low of $0.66 and a high of $3.09, while posting a quarterly EPS of ($0.12) that exceeded expectations.

Bain Capital Life Sciences Investors LLC lessened its stake in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Free Report) by 39.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,072,421 shares of the company's stock after selling 686,579 shares during the quarter. Nautilus Biotechnology comprises 0.1% of Bain Capital Life Sciences Investors LLC's investment portfolio, making the stock its 23rd biggest holding. Bain Capital Life Sciences Investors LLC owned about 0.85% of Nautilus Biotechnology worth $923,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently made changes to their positions in NAUT. XTX Topco Ltd bought a new position in shares of Nautilus Biotechnology during the 1st quarter worth about $31,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Nautilus Biotechnology in the 4th quarter worth about $34,000. Fayez Sarofim & Co bought a new position in Nautilus Biotechnology in the 1st quarter valued at about $39,000. Squarepoint Ops LLC bought a new position in Nautilus Biotechnology in the 4th quarter valued at about $44,000. Finally, Deutsche Bank AG lifted its position in Nautilus Biotechnology by 145.2% in the 1st quarter. Deutsche Bank AG now owns 54,839 shares of the company's stock valued at $47,000 after acquiring an additional 32,470 shares in the last quarter. Institutional investors own 50.71% of the company's stock.

Nautilus Biotechnology Trading Up 1.4%

NASDAQ NAUT traded up $0.01 during trading hours on Friday, hitting $0.66. The company's stock had a trading volume of 309,080 shares, compared to its average volume of 176,910. The company has a market capitalization of $83.49 million, a PE ratio of -1.27 and a beta of 1.42. The company's 50-day simple moving average is $0.73 and its two-hundred day simple moving average is $0.82. Nautilus Biotechnology, Inc. has a 52 week low of $0.62 and a 52 week high of $3.09.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02. Research analysts anticipate that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current fiscal year.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.